로딩 중…
StockDiggingStockDigging

Boditech Med Inc.

206640· KOSDAQ
₩10,650-0.84%
2026-06-19

Price Chart

Boditech Med Inc.-29.47%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap233.32B KRW
Revenue165.84B KRW
Net Income1.27B KRW
Total Assets296.01B KRW
Net Assets255.10B KRW
Employees532
Value
P/E184.20x
P/B0.91x
PEG5.95x
P/S1.41x
EV/EBITDA57.46x
FCF Yield-4.69%
Profitability
ROE0.50%
ROA0.43%
Op. Margin2.28%
Revenue Growth9.58%
Earnings Growth30.96%
Financial Health
Debt Ratio116.04%
Total Debt23.53B KRW
FCF-10.93B KRW
Cash39.74B KRW
Current Ratio5.55x
Net Debt/EBITDA-4.29x
Dividend
Div. Yield1.40%
Div. Growth0.00%
Performance
1Y Return-29.47%
1M Return-2.74%
From 52W High-32.59%
1Y MDD-41.74%
Trading
Volume58,388 shares
Foreign Own.2.98%
Per Share
EPS1,118 KRW
BPS11,130 KRW

Company Info

CEO 최의열
Employees 532
Founded 2014
HQ 강원도 춘천시, KR

Boditech Med, established in 1998 as an in-vitro diagnostics specialist, operates production corporations in the US and China, expanding its diagnostics market. Leveraging lateral flow immunofluorescence technology, the company possesses over 100 types of disease diagnostic product lines and has diversified sales channels by establishing sales networks in over 130 countries worldwide. It has developed next-generation and automated immunoassay platforms, laying the groundwork for entry into advanced markets and large hospitals, and is aspiring to become a global diagnostics company through the development of high-value-added diagnostic cartridges. Its headquarters are in Chuncheon-si, Gangwon-do.